IGF-1 LR3 research

The IGF-1 LR3 evidence base cited here is 5 sources — 4 preclinical, 1 review. Critically, that evidence is almost entirely preclinical (animal and in-vitro) — no human clinical trials are cited, so efficacy and safety in people remain unproven. Regulatory status: Not FDA-approved (never tested in humans).

• IGF-1 LR3 is a synthetic, more-potent analog of insulin-like growth factor-1 — it has NEVER been approved for human use anywhere, and there have been ZERO human clinical trials.
• An N-terminal extension and an R3 substitution reduce its binding to IGF-binding proteins, leaving more free, active hormone and giving a long ~20–30 hour half-life — roughly 3× the potency of native IGF-1.
• The safety record is unusually alarming for the preclinical literature: documented animal deaths from prolonged hypoglycemia, plus species-dependent and even paradoxical (growth-inhibiting) responses. Human response is genuinely unknown.

IGF-1 LR3 (Long R3 IGF-1) is an 83-amino-acid engineered version of IGF-1 designed to circulate longer and act more potently than the native hormone. It sits downstream of the GH axis as the effector — where HGH stimulates IGF-1, IGF-1 LR3 IS the IGF-1 signal, amplified.

This profile is deliberately safety-forward: there are no human trials, the preclinical record includes animal deaths, and the compound is strictly a research chemical. Everything below is research context, not medical guidance.

IGF-1 LR3 is an 83-amino-acid analog of human IGF-1 with two key modifications: an N-terminal 13-amino-acid extension and an arginine substituted at position 3 (the 'R3'). Together these sharply reduce its binding to the IGF-binding proteins (IGFBPs) that normally sequester IGF-1, so more of it stays free and active — the basis for both its ~3× potency and its long ~20–30 hour half-life.

It is a full IGF-1 receptor agonist, activating the PI3K/Akt/mTOR and MAPK/ERK pathways that drive growth and protein synthesis.

By evading IGFBP sequestration, IGF-1 LR3 maintains high free-IGF-1 activity at the receptor for a long window. In animal models this activates satellite cells and protein synthesis (the basis for the muscle-hypertrophy and even hyperplasia claims) and exerts anti-catabolic effects. The same potency and IGFBP-evasion, however, is what makes its glucose effects dangerous — IGF-1 has insulin-like activity, and sustained high levels can drive severe, prolonged hypoglycemia.

This is the most safety-cautionary compound in the GH-axis set. The dominant acute risk is severe, prolonged hypoglycemia (animal studies documented deaths). It carries a cancer-proliferation concern — elevated IGF-1 is epidemiologically linked to several cancers, and it could accelerate an existing or undiagnosed tumor — so it is contraindicated with any cancer history or undiagnosed growths. Prolonged use may cause organ hypertrophy (heart, intestines). It is WADA-prohibited. Critically, animal responses are species-dependent (effective in rats, growth-inhibiting in pigs), so the human response is unknown.

• Fetal sheep metabolic study: infusion suppressed insulin ~66% acutely; the chronic arm was halted after animal deaths from hypoglycemia/hypoxemia.

There are zero human trials. Every figure above is animal data, and the safety findings include deaths — read any efficacy claim against that backdrop.

IGF-1 LR3 has never been approved for human use in any country. It is sold strictly as a research chemical, not intended for human consumption, and is prohibited in competitive sport (WADA).

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.